Even if Humira having a more than five-year market headstart, its standard of care status is not set in stone.
LoA Update: BMS’ Opdivo/relatlimab combination gets boost in approval likelihood in 1L melanoma after Phase II/III results at ASCO
The Likelihood of Apporval (LoA) for Bristol Myers Squibb’s Opdivo (nivolumab) combo with the anti-LAG3 antibody relatlimab climbed by 10 points to 49%, as of 9 June.
LoA Update: Incyte’s topical ruxolitinib has 15-point hike in approval likelihood in vitiligo after Phase III data reveal
Incyte’s ruxolitinib saw a 15-point jump on its Likelihood of Approval (LoA) in vitiligo on the back of positive topline data from two Phase III trials.
The National Institutes of Health (NIH) has announced the start of a Phase IIb clinical trial of existing antibiotic dalbavancin for treating complicated Staphylococcus aureus (S. aureus) bacteremia.
AstraZeneca has dosed the first subjects in three clinical trials of monoclonal antibody Fasenra (benralizumab) for the treatment of skin diseases.
LoA Update: Ortho Dermatologics’ FDA approval potential for its acne gel jumps 12 points after Phase III meets primary endpoint
Ortho Dermatologics’ topical gel IDP-120 for moderate-to-severe acne vulgaris saw a 12-point increase in its Likelihood of Approval (LoA) due to its Phase III trial meeting its primary endpoint.